A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Recruiting

Phase 1

Voruciclib & VenetoclaxA Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Sponsor:

MEI Pharma, Inc.

Code:

NCT03547115

Conditions

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Marginal Zone Lymphoma (MZL)

Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

voruciclib monotherapy

voruciclib and venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-23. This information was provided to ClinicalTrials.gov by MEI Pharma, Inc. on 2023-08-07.